This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Albers GW, Amarenco P (2001): Combination therapy with clopidogrel and aspirin. Can the CURE results be extrapolated to cerebrovascular patients? Stroke 32: 2948–2949.
Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ (2001): Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001 (4): CD 001342.
Antithrombotic Trialists’ Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86.
Bertrand ME, Rupprecht H-J, Urban P, Gershlick AH for the CLASSICS Investigators (2000): Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102: 624–629.
Born GVR, Collins R (1997): Aspirin versus clopidogrel: the wrong question? Lancet 349: 806–807.
CAPRIE Steering Committee (1996): A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339.
Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005): Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244.
De Schryver ELLM, Algra A, van Gijn MD (2003): Cochrane Review: Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 34: 2072–2080.
Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators (2004): Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, doubleblind, placebo-controlled trial. Lancet 364: 331–337.
Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996): European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1–13.
Eikelboom JW, Anand SS, Maimberg K, Weitz JI, Ginsberg JS, Yusuf S (2000): Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355: 1936–1942.
Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2003): Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650–1655.
Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC et al. (1989): The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet I: 1215–1220.
Gorelick PB, Born GVR, d’Agostino RB, Hanley DF Jr, Moye L, Pepine CJ (1999): Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. Stroke 30: 1716–1721.
Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, Selfa S (2001): Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. Am J Hematol 67: 10–14.
Gum PA, Kottke-Marchant K, Poggio ED, et al. (2001): Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88: 230–235.
Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA et al. (1989): A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321: 501–507.
Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS (2003): Aspirin and clopidogrel in acute coronary syndromes. Therapeutic insights from the CURE study. Arch Intern Med 163: 1145–1153.
Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R (2004): Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess (38): iii–iv, 1–196.
Keng TB (2001): Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. Br J Haematol 114: 394–396.
Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM et al. (1996): Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334: 682–687.
Lensing AWA, Prins MH, Davidson BL, Hirsh J (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 155: 601–607.
Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL et al. (1998): A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339: 1665–1671.
Levine M, Gent M, Hirsh J, Leclerc J, Anderson D et al. (1996): A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334: 677–681.
Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BL, Katarajan MK et al. for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001): Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients underoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358: 527–533.
Mismetti P, Laporte S, Darmon J-Y, Buchmüller A, Decousus H (2001): Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88: 913–930.
Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S et al. (1999): Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99: 2364–2366.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001): Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 345: 494–502.
Van der Heijden JF, Hutten BA, Büller HR, Prins MH (2002): Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Revies). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
Walenga JM (2002): Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 105: 401–405.
White RH, Ginsberg JS (2003): Low-molecular-weight heparins: are thy all the same? Br J Hematol 121: 12–20.
Zed PJ, Tisdale JE, Borzak S (1999): Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 159: 1849–1857.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2006). Antikoagulantien und Thrombozytenaggregationshemmer. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2005. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-30505-X_16
Download citation
DOI: https://doi.org/10.1007/3-540-30505-X_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-28368-3
Online ISBN: 978-3-540-30505-7
eBook Packages: Medicine (German Language)